share_log

CORRESP: CORRESP

CORRESP: CORRESP

CORRESP:信函
美股SEC公告 ·  2024/10/31 11:39

Moomoo AI 已提取核心信息

On October 31, 2024, Conduit Pharmaceuticals, led by CEO David Tapolczay, requested the U.S. Securities and Exchange Commission (SEC) to expedite the effectiveness of its Registration Statement on Form S-3. The company aims for the statement to become effective on November 1, 2024, at 4:30 p.m. Eastern Time.This request is made under Rule 461 of the Securities Act of 1933. The company has appointed Todd Mason of Thompson Hine LLP as the contact for any inquiries related to this request. The effectiveness of the Registration Statement is crucial for Conduit Pharmaceuticals' strategic financial planning and potential capital raising activities.
On October 31, 2024, Conduit Pharmaceuticals, led by CEO David Tapolczay, requested the U.S. Securities and Exchange Commission (SEC) to expedite the effectiveness of its Registration Statement on Form S-3. The company aims for the statement to become effective on November 1, 2024, at 4:30 p.m. Eastern Time.This request is made under Rule 461 of the Securities Act of 1933. The company has appointed Todd Mason of Thompson Hine LLP as the contact for any inquiries related to this request. The effectiveness of the Registration Statement is crucial for Conduit Pharmaceuticals' strategic financial planning and potential capital raising activities.
2024年10月31日,由首席执行官戴维·塔波尔扎伊领导的Conduit Pharmicalsumicals要求美国证券交易委员会(SEC)加快其S-3表格注册声明的生效。该公司的目标是该声明于美国东部时间2024年11月1日下午 4:30 生效。该请求是根据1933年《证券法》第461条提出的。该公司已任命汤普森·海因律师事务所的托德·梅森为与该请求有关的任何查询的联系人。注册声明的有效性对于Conduit Pharmaceuticals的战略财务规划和潜在的筹资活动至关重要。
2024年10月31日,由首席执行官戴维·塔波尔扎伊领导的Conduit Pharmicalsumicals要求美国证券交易委员会(SEC)加快其S-3表格注册声明的生效。该公司的目标是该声明于美国东部时间2024年11月1日下午 4:30 生效。该请求是根据1933年《证券法》第461条提出的。该公司已任命汤普森·海因律师事务所的托德·梅森为与该请求有关的任何查询的联系人。注册声明的有效性对于Conduit Pharmaceuticals的战略财务规划和潜在的筹资活动至关重要。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息